Drug intelligence / Profile preview

SIM0520

Development stage: Preclinical
Lead developer: Simcere Pharmaceutical Group
Modality: Small Molecules

Overview

SIM0520 is an investigational small molecule inhibitor of DNA polymerase theta (Polθ), developed by Simcere Pharmaceutical and its subsidiary Shandong Simcere Medgenn. Polθ is a specialized DNA polymerase that plays a critical role in the microhomology-mediated end joining (MMEJ) pathway, a DNA repair mechanism that becomes essential in cancer cells with homologous recombination deficiency (HRD), such as those harboring BRCA1 or BRCA2 mutations. By targeting Polθ, SIM0520 aims to exploit synthetic lethality, selectively killing HR-deficient tumor cells while sparing healthy tissue. The drug is currently in preclinical development for the treatment of solid tumors, potentially as a monotherapy or in combination with PARP inhibitors or other DNA-damaging agents.

Other names: S(AL)-4

Targets

POLQ (DNA polymerase theta)

Beyond the preview

Go deeper on SIM0520.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SIM0520.

Explore the full profile